PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-9,1994,3643,523
Cost of Revenue-8,398730630
Gross Profit-8013,6342,893
Operating Expenses
Research Development28,05923,60819,02521,224
Selling General and Administrative12,30510,3568,27910,228
Non Recurring----
Total Operating Expenses-42,36228,03432,082
Operating Income or Loss--33,163-23,670-28,559
Income from Continuing Operations
Total Other Income/Expenses Net-47,5983,987-3,612-4,739
Earnings Before Interest and Taxes--33,163-23,670-28,559
Interest Expense-572-3,364-3,549-3,549
Income Before Tax--29,176-27,282-33,298
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops--29,176-27,282-33,298
Non-recurring Events
Discontinued Operations--18985,3193,355
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income--29,36558,037-29,943
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares--29,36558,037-29,943